• 22 FEB 16
    • 0

    Research into genetic causes in painful neuropathy.

    Neuropathic pain is a frequent feature of peripheral neuropathy, adversely impacting patients’ quality of life. Not all individuals with peripheral neuropathy develop pain and it is not possible to predict who will develop pain. Moreover, current treatments are often disappointing. The PROPANE (Probing the role of sodium channels in painful neuropathies) Study aims to find new genes involved in the development of painful neuropathy resolving its genetic architecture. Hereby achieving a stratification of high-risk neuropathic pain patients by novel biomarkers, to deepen understanding of underlying mechanisms and druggable targets. Furthermore identifying new molecules tailored to potentially drug-responder patients and determining their effects in pre-clinical settings. Results will advance the field beyond the current state-of-the-art, opening a window upon a validated individualized pain medicine and having an innovative impact both on patients’ care and market applications. These aims will be achieved by a complementary approach based on targeted sequencing of the 5 sodium channel genes expressed in the nociceptive pathway and identification of new targets by unbiased whole exome sequencing and transcriptome assay. Melding of these two approaches offers a close-to-optimal balance between highly focused, challenging but clearly achievable goals (sodium channels in pain) and a broader unbiased approach that will capture and deliver other targets and approaches from our unique patient population. Our strong preliminary findings were the starting point of the PROPANE STUDY and the expected results could be translated into solutions able to benefit a large population of pain patients in terms of diagnosis and treatment.

    Leave a reply →